Drugs / BHQ880
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00741377 | Jan 2009 → Dec 2011 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01337752 | Jan 2012 → May 2013 | impaired renal function disease, plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01302886 | May 2011 → Nov 2013 | smoldering plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHQ880 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01302886 ↗ |
| Action | Inhibit | “Anti-Dickkopf1 (DKK1) Neutralizing Antibody” NCT01302886 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody (mAb)” NCT01337752 ↗ |
| Route | Intravenous | “repeated IV doses of BHQ880” NCT00741377 ↗ |
| Target | DKK1 | “Anti-Dickkopf1 (DKK1) Neutralizing Antibody” NCT01302886 ↗ |